Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Sets Goal Of 45% Of Sales Outside Of Japan By 2002

Executive Summary

Eisai aims to double sales outside of Japan within three years, Eisai U.S. President Soichi Matsuno told a recent Warburg Dillon Read analysts conference.

You may also be interested in...



Eisai/Janssen Aciphex Sales Closing In On $250 Mil. 13 Months After Launch

Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS035036

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel